Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Abivax Announces Modifications To Its Phase 2 Development Program Of Obefazimod In Crohn's Disease, To Align With Recent FDA Feedback

Author: Benzinga Newsdesk | February 02, 2024 03:55am

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease

Obefazimod Crohn's Disease (CD) IND filed with the FDA in December 2023 and cleared to proceed
In alignment with FDA feedback, Abivax to modify CD trial design and conduct dose ranging Phase 2b clinical trial
Start of patient enrollment planned for Q3 2024
12-week induction data read-out expected in 2H 2026

Posted In: ABVX